Vera C Mazurak
Overview
Explore the profile of Vera C Mazurak including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
80
Citations
1575
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Klassen P, Mazurak V, Baracos V, Martin L, Ghosh S, Kasnik J, et al.
Clin Nutr
. 2024 Jul;
43(8):1900-1906.
PMID: 38991415
Background & Aims: Exocrine pancreatic insufficiency (EPI) contributes to malnutrition, marked by muscle loss during chemotherapy for advanced pancreatic cancer (aPC). Pancreatic enzyme replacement therapy (PERT) is recommended for patients...
2.
Mazurak V, Rivas-Serna I, Parsons S, Monirujjaman M, Maybank K, Woo S, et al.
Sci Rep
. 2023 Nov;
13(1):18973.
PMID: 37923927
It is important for allocation of resources to predict those COVID patients at high risk of dying or organ failure. Early signals to initiate cellular events of host immunity can...
3.
Abdurrahim A, Mazurak V, Chen L
Front Nutr
. 2023 Sep;
10:1229015.
PMID: 37743923
Oxidative stress caused by free radicals contributes to the pathogenesis of multiple chronic health conditions. Phytochemicals protect against oxidative stress; however, low bioavailability from dietary sources limits their health benefits....
4.
Klassen P, Baracos V, Ghosh S, Martin L, Sawyer M, Mazurak V
Cancers (Basel)
. 2023 Sep;
15(17).
PMID: 37686641
Muscle and adipose wasting during chemotherapy for advanced pancreatic cancer (aPC) are associated with poor outcomes. We aimed to quantify the contributions of chemotherapy regimen and tumour progression to muscle...
5.
Klassen P, Mazurak V, Thorlakson J, Servais S
J Cachexia Sarcopenia Muscle
. 2023 Sep;
14(5):1918-1931.
PMID: 37675809
Investigators are increasingly measuring skeletal muscle (SM) and adipose tissue (AT) change during cancer treatment to understand impact on patient outcomes. Recent meta-analyses have reported high heterogeneity in this literature,...
6.
Monirujjaman M, Renani L, Isesele P, Dunichand-Hoedl A, Mazurak V
Int J Mol Sci
. 2023 Feb;
24(4).
PMID: 36834959
Cancer treatment evokes impediments to liver metabolism that culminate in fatty liver. This study determined hepatic fatty acid composition and expression of genes and mediators involved in lipid metabolism following...
7.
Monirujjaman M, Bathe O, Mazurak V
Cancers (Basel)
. 2022 Nov;
14(22).
PMID: 36428795
Irinotecan (CPT-11) and 5-fluorouracil (5-FU) are commonly used to treat metastatic colorectal cancer, but chemotherapy-associated steatosis/steatohepatitis (CASSH) frequently accompanies their use. The objective of this study was to determine effect...
8.
Vaughen J, Theisen E, Rivas-Serna I, Berger A, Kalakuntla P, Anreiter I, et al.
Neuron
. 2022 Aug;
110(19):3186-3205.e7.
PMID: 35961319
Structural plasticity in the brain often necessitates dramatic remodeling of neuronal processes, with attendant reorganization of the cytoskeleton and membranes. Although cytoskeletal restructuring has been studied extensively, how lipids might...
9.
Ebadi M, Dunichand-Hoedl A, Rider E, Kneteman N, Shapiro J, Bigam D, et al.
JHEP Rep
. 2022 May;
4(7):100495.
PMID: 35600667
Background & Aims: Association between sarcopenia and mortality in cirrhosis is well recognised; however, little is known about the clinical implications of adipose tissue radiodensity, indicative of biological features. This...
10.
Ebadi M, Tsien C, Bhanji R, Dunichand-Hoedl A, Rider E, Motamedrad M, et al.
Cells
. 2022 Apr;
11(8).
PMID: 35456024
Myosteatosis (pathological fat accumulation in muscle) is defined by lower mean skeletal muscle radiodensity in CT. We aimed to determine the optimal cut-offs for myosteatosis in a cohort of 855...